"Designing Growth Strategies is in our DNA"
The global injectable cytotoxic drugs market size was USD 15.81 billion in 2019. The global impact of COVID-19 has been unprecedented and staggering, with injectable cytotoxic drugs witnessing a positive demand shock across all regions amid the pandemic. Based on our analysis, the global market will exhibit a moderate growth of 8.5% in 2020. The market is projected to grow from USD 17.16 billion in 2020 to USD 29.60 billion in 2027 at a CAGR of 8.1% between 2020-2027. The fall in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.
Cytotoxic drugs are one of the vital drug classes used to treat prevalent diseases such as oncology disorders. These drugs are known for their cellular degeneration property that help to eradicate cancerous cells. Cytotoxic injectable medicines are prescribed as the first line of treatment for various types of cancer. The majority of the injectable cytotoxic drugs that are off-patent are available as generics in the global market. Cytotoxic drugs, also known as chemotherapy, are identified for their severe side effects such as bone marrow depression, follicle toxicity, and anemia. The increasing prevalence of cancer and high dependency on cytotoxic drugs for its treatment are predominant factors augmenting the growth of the market in the coming years. For instance, as per the American Cancer Society report, the majority of oncology disorders such as bladder, breast, testicular, uterus, etc. require chemotherapy from stage 2 itself.
COVID-19 Pandemic to Increase Demand for Cytotoxic Drugs
The outbreak of COVID-19 has had a positive impact on the injectable cytotoxic drugs market globally. Certain market segments have witnessed a growth in demand for drugs with respect to the COVID-19 emergency. The pharmaceutical companies involved in this market have significantly improved their supply chain management, enhanced their R&D, and invested more in production and quality control. According to the quarterly reports of 2020 of Roche, their global supply chain of medicines and tests remain intact. Their pharmaceutical division sales increased by 7% as compared to the prior year. This growth was led by oncology drugs such as Tecentriq and Perjeta.
Request a Free sample to learn more about this report.
Strategic Collaborations among Industry Players is a Vital Trend
The Healthcare landscape has significantly changed owing to the collaborative approach between the non-traditional key players and the existing traditional players to provide a more customer-centric experience. Partnerships between the key players operating in the cytotoxic drugs market and pharmacy distributors have improved the healthcare supply chain’s productivity and are one of the key market trends. In November 2019, Bristol-Myers Squibb Company announced that it had completed Celgene’s acquisition, leading to the creation of a strong biopharmaceutical entity, due to the companies’ strong complementary portfolios of oncology, immunology, inflammation, and cardiovascular disease.
High Dependency on Cytotoxic Drugs for Treatment of Disease Indication to Propel Market Growth
Cancer is a devastating disease, and due to disease heterogeneity, standard treatments such as chemotherapy or radiation are effective and highly adopted among the population. Additionally, cytotoxic drugs are predominantly used as the first line of treatment for a newly diagnosed cancer patient. The upcoming therapies, such as targeted therapy and immunotherapy, are currently only approved to treat specific cancer types. Additionally, most targeted and immunotherapy drugs are prescribed in combination with cytotoxic/ chemotherapy drugs. Cytotoxic drugs are also defined in patients with aggravated forms of multiple sclerosis.
Combined with this, there are a significant number of pipeline molecules under development that are indicated to be prescribed along with cytotoxic drugs. For instance, EMD Serono Research & Development Institute, Inc, in collaboration with Merck KGaA, is developing M4344. The molecule is in Phase 1 clinical trial combined with Carboplatin for the treatment of advanced solid tumors.
Surge in the Cancer and Rheumatoid Arthritis to Boost the Market Growth
Worldwide, cancer prevalence has increased tremendously to make it the second leading cause of death after cardiovascular disease. Environmental factors such as tobacco smoking, urbanization, and its associated pollution, and changing diet patterns are considered responsible for this phenomenon. For instance, according to the World Health Organization (WHO), cancer is a growing burden. The number of new cancer cases is expected to rise from 18.1 million in 2018 to 29.4 million by 2040.
Globally there is also a surge in the prevalence of rheumatoid arthritis and multiple sclerosis. This rise is estimated to increase the adoption of cytotoxic drugs in the treatment of the disease. According to the Center for Disease Control and Prevention, around 41 individuals out of 100,000 are affected with rheumatoid arthritis each year in the U.S.
Advent of Alternate Therapies to Treat Cancer Could Restrain the Market
The upcoming novel therapies focused on immunotherapy and targeted therapy are highly efficacious and also exhibit lower side effects than cytotoxic drugs. These factors are likely to inhibit the growth of the injectable cytotoxic drugs market in the forthcoming years. The inherent variability of cancer contributes to the growing field of precision and personalized medicine (PPM). PPM cancer treatments have been proven to result in immense patient benefits, and thus various pharmaceutical companies are investing in this space. For instance, in June 2020, Philips and The University of Texas MD Anderson Cancer Center collaborated to facilitate personalized oncology treatments and clinical trials matching based on genomic markers.
To know how our report can help streamline your business, Speak to Analyst
Prophylaxis Segment Held the Highest Market Share in 2019
Based on drug class, the market is categorized into alkylating drugs, cytotoxic antibodies, antimetabolites, plant alkaloids, and others. The antimetabolites segment dominated the market in 2019. Antimetabolites are one of the most prescribed cytotoxic drugs for oncology and rheumatoid diseases. The higher adoption of this drug class is estimated to propel the segment growth in the coming years.
On the other hand, plant alkaloids hold the second-largest share in the global market. More than 95% of the plant alkaloids are administered through the infusion of IV. These factors are projected to drive the segment growth during the study period.
The market has been categorized into oncology, multiple sclerosis, rheumatoid arthritis, and others based on application. Among the applications, the oncology segment dominated the global market. The segment’s growth is driven by the ever-rising prevalence of cancer and the use of oncology drugs to treat the disease indication. Combined with this, high dependency on cytotoxic drugs to treat cancer is also a predominant factor influencing the growth of the segment in the forthcoming years.
Hospital Pharmacy Segment Dominated the Market in 2019
Based on end-users, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among the end-users, the hospital pharmacy segment dominated the global market. The segment's growth is influenced by the factor that the majority of the injectable cytotoxic drugs require administration of the molecule by a healthcare professional. Hence, the segment is also estimated to have the highest CAGR in the coming years.
North America Injectable Cytotoxic Drugs Market Size, 2019 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
The market size in North America stood at USD 7.69 billion in 2019 and will grow considerably during the forecast period. The growth is attributable to the higher number of cancer patients and more extensive access to cancer drugs. For Instance, according to the American Cancer Society, in 2019, an estimated 268,600 new cases of invasive breast cancer were diagnosed in women, and about 2,670 cases were diagnosed in men in the U.S alone.
The growth of the market in Europe is attributable to various factors such as high healthcare expenditure on cancer and rheumatoid arthritis, favorable reimbursement policies, and active government initiatives to increase the accessibility of chemotherapy drugs, among others. According to the article published in the European Journal of Cancer, the European countries spent about US$ 243.6 Bn for cancer in 2018. Such increasing expenditures will propel the market growth in the region.
On the other hand, the Asia Pacific market is anticipated to showcase significant growth during the forecast duration. Factors, such as an increasing patient pool and expanding healthcare spending in the region, are supplementing the market growth in Asia Pacific. Moreover, the growing purchasing power of the masses in the emerging economies, namely, India and China, provides a huge opportunity for the market's growth.
Considerable growth in the injectable cytotoxic drugs market is anticipated during the forecast years in Latin America, and the Middle East and Africa. Countries in the region, including Latin America, and the Middle East and Africa are witnessing an increase in the demand for cancer, multiple sclerosis, and rheumatoid arthritis treatment options to cope up with the exponentially increasing patient population suffering from such diseases.
Key Companies to Focus on Launching Cost-effective Treatment Options
The global market is fragmented and highly competitive with local as well as international players operating in the market. The market was dominated by Johnson and Johnson Services, Inc., garnering a majority share in 2019. The company’s high focus on mergers and acquisitions to diversify its product portfolio is a predominant reason for its dominance in the market. Moreover, regular product approvals and the entrance of medium-sized companies are anticipated to increase the competition between the players. For instance, in December 2020, MacroGenics, Inc. received U.S FDA approval for its product MARGENZA to treat adult patients with metastatic HER2-positive breast cancer. Other players operating in the market include Sanofi, Eli Lily, and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer, Inc., among others. These players also play a key role in the pharmaceutical industry.
An Infographic Representation of Injectable Cytotoxic Drugs Market
To get information on various segments, share your queries with us
The injectable cytotoxic drugs market report provides qualitative and quantitative insights on the injectable cytotoxic drugs industry and a detailed analysis of market size and growth rate for all possible segments in the market. Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights are the prevalence of cancer by key regions, key industry developments, an overview of regulatory scenarios, pipeline analysis, and analysis of COVID-19 on the global market, among others.
Value (USD billion)
By Drug Class
Fortune Business Insights says that the global market size was USD 15.81 billion in 2019 and is projected to reach USD 29.60 billion by 2027.
In 2019, the North American market stood at USD 7.69billion.
The market will exhibit a moderate growth rate of 8.1% during the forecast period (2020-2027).
The antimetabolites drug segment dominated the global market in 2019.
The increasing prevalence of cancer, rheumatoid arthritis, and multiple sclerosis will drive the growth of the market.
Johnson and Johnson, Sanofi, and Bristol-Myers Squibb Company are the major players in the global market.
North America dominated the market in terms of share in 2019.
New product launches and mergers, and acquisitions in the market are expected to drive the adoption of injectable cytotoxic drugs.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry